Black Diamond Therapeutics, Inc.
BDTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
11dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
BDTX Earnings Report
EPS Est: $-0.18 | FQ end 2026-06
How BDTX's past catalysts played out
silevertinib (BDTX-1535) monotherapy
Non-Small Cell Lung Cancer
silevertinib in combination with temozolomide
Glioblastoma (GBM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
silevertinib in combination with temozolomide | Phase 2 | Glioblastoma (GBM) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Black Diamond Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Black Diamond Therapeutics, Inc.'s (BDTX) pipeline across Phase 2. Its lead program is silevertinib (BDTX-1535) monotherapy (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Black Diamond Therapeutics, Inc.'s next FDA catalyst?→
Black Diamond Therapeutics, Inc.'s (BDTX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BDTX biotech catalysts?→
Add BDTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Black Diamond Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.